NeyroblastGX, founded in 2020 and headquartered in Murrieta, California, is a biotechnology company specializing in theranostic products aimed at treating neurodegenerative and infectious diseases. The company's core mission is to advance medical science through innovative solutions that combine therapeutic and diagnostic capabilities. NeyroblastGX offers high-quality human-induced pluripotent stem cells (HiPSCs) for rapid differentiation and downstream analysis, catering to researchers and healthcare providers focused on neurodegenerative conditions.

NeyroblastGX has attracted attention from notable figures in the biotech industry and has secured investments from key players committed to advancing medical research. Among its significant achievements, the company has successfully developed a range of HiPSCs that are highly efficient and available at a discount for first-time buyers, demonstrating its commitment to accessibility and innovation. NeyroblastGX's impact is reflected in its contribution to the field of neurodegenerative disease research, providing essential tools that facilitate groundbreaking studies and potential treatments.